In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
How Hong Kong is cracking down on dissent
As conflict rages in Gaza, a ‘silent war’ in the West Bank
The capital gains tax, explained
ArriveCan and the government’s outsourcing problem
The stakes of India’s election as Modi seeks third term
What the 2024 federal budget means for you
How a new kind of drug could change the future of Alzheimer’s
City Space: How Halifax’s unhoused crisis got so bad
What we’ve learned from the foreign interference inquiry
Former health minister Jane Philpott’s plan to save health care
Why major economies are trying to woo Vietnam
How seafood from North Korean forced labour ends up in Canada
The deadly challenges of getting aid into Gaza
School boards take on social media giants
Canada’s uncertain AI future
Four reasons why you can’t afford housing
What to know about the upcoming total solar eclipse
How sleep affects our brains
Amid a housing crisis, students build tiny homes for teachers
Create your
podcast in
minutes
It is Free
As It Happens
The Daily
Morning Wire
Up First
Dobré ráno | Denný podcast denníka SME